Research blood sample

PROCEDURE2 trials

Sponsors

Washington University School of Medicine

Conditions

Breast CancerBreast CarcinomaBreast NeoplasmsCancer of Breast

Phase 2

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

CompletedNCT01670877

Washington University School of MedicineBreast Neoplasms

Start: 2012-12-11End: 2021-03-11Updated: 2022-04-15

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

TerminatedNCT02907918

Washington University School of MedicineBreast Cancer, Breast Carcinoma, Cancer of Breast

Start: 2017-06-30End: 2020-09-23Updated: 2021-09-29

Related Papers

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Clinical Cancer Research2023-06-2612 citations

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).

2023-01-0613 citations

Mechanisms of neratinib resistance in <i>HER2</i>-mutant metastatic breast cancer.

2022-09-019 citations

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.

2022-02-1815 citations

Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)

Cancer Research2022-02-153 citations

Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer

Cancer Research2022-02-151 citations

Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

JCO Precision Oncology2019-11-157 citations

Abstract 4459: Morphologic and genomic characterization of circulating tumor cells in patients with <i>ERBB2</i> mutant HER2 non-amplified metastatic breast cancer treated with neratinib

Cancer Research2019-07-01

Abstract 4459: Morphologic and genomic characterization of circulating tumor cells in patients with<i>ERBB2</i>mutant HER2 non-amplified metastatic breast cancer treated with neratinib

Clinical Research (Excluding Clinical Trials)2019-07-01

Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice

Cancer Research2019-02-15

Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib.

Journal of Clinical Oncology2017-05-20

Oncology Times2016-08-09

Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2<sup>mut</sup> MBC).

Journal of Clinical Oncology2016-05-2016 citations

Breast Cancer Research 2013

Oncology Times2014-02-0124 citations